Evidence map›Paper›PMID 38356648›Full record

ReviewFrontiers in neuroscience2024

Can pluripotent/multipotent stem cells reverse Parkinson's disease progression?

Yongkang Wu, Xiangtian Meng, Wai-Yin Cheng, Zhichao Yan, Keqin Li, Jian Wang, Tianfang Jiang, Fei Zhou, Ka-Hing Wong, Chunlong Zhong and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.Movement disorders : official journal of the Movement Disorder Society · 2025
    Trial
  2. Article
  3. Review
  4. Association between dietaryFrontiers in nutrition · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Yongkang Wu *Key Laboratory of Adolescent Health Evaluation and Sports Intervention, Ministry of Education, East China Normal University, Shanghai, China.
Xiangtian Meng *Department of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Wai-Yin ChengResearch Institute for Future Food, The Hong Kong Polytechnic University, Hong Kong, Hong Kong SAR, China.
Zhichao YanDepartment of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Keqin LiDepartment of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jian WangDepartment of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Tianfang JiangDepartment of Neurology, Shanghai Eighth People's Hospital Affiliated to Jiangsu University, Shanghai, China.
Fei ZhouDepartment of Neurology, Third Affiliated Hospital of Navy Military Medical University, Shanghai, China.
Ka-Hing WongResearch Institute for Future Food, The Hong Kong Polytechnic University, Hong Kong, Hong Kong SAR, China.
Chunlong ZhongDepartment of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yi DongKey Laboratory of Adolescent Health Evaluation and Sports Intervention, Ministry of Education, East China Normal University, Shanghai, China.
Shane GaoDepartment of Neurosurgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Shanghai East Hospital · CNEast China Normal University · CNHong Kong Polytechnic University · HKJiangsu University · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by continuous and selective degeneration or death of dopamine neurons in the midbrain, leading to dysfunction of the nigrostriatal neural circuits. Current clinical treatments for PD include drug treatment and surgery, which provide short-term relief of symptoms but are associated with many side effects and cannot reverse the progression of PD. Pluripotent/multipotent stem cells possess a self-renewal capacity and the potential to differentiate into dopaminergic neurons. Transplantation of pluripotent/multipotent stem cells or dopaminergic neurons derived from these cells is a promising strategy for the complete repair of damaged neural circuits in PD. This article reviews and summarizes the current preclinical/clinical treatments for PD, their efficacies, and the advantages/disadvantages of various stem cells, including pluripotent and multipotent stem cells, to provide a detailed overview of how these cells can be applied in the treatment of PD, as well as the challenges and bottlenecks that need to be overcome in future translational studies.

Indexed as

dopaminemultipotent stem cellsParkinson’s diseasepluripotent stem cellstransplantation

Identifiers

PMID38356648
PMCPMC10864507
OpenAlexW4391397905

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.